Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy

NCT04106167 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT04106167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04106167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Lead sponsor
Fate Therapeutics
Phase
Observational
Overall status
Terminated
Start date
June 11, 2019
Completion date
August 11, 2023
Enrollment
20 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cervical cancer, colorectal cancer, egfr positive solid tumor, gastric cancer, head and neck cancer, hepatocellular carcinoma, her2-positive breast cancer, lymphoma, melanoma, merkel cell carcinoma, microsatellite instability, nsclc, pancreas cancer, renal cell carcinoma, small-cell lung cancer, squamous cell carcinoma, urothelial carcinoma